Skip to content

Study on the efficacy and central regulation mechanism of rTMS based on fMRI-guided individualized target in the treatment of chronic insomnia disorder

Study on the efficacy and central regulation mechanism of rTMS based on fMRI-guided individualized target in the treatment of chronic insomnia disorder

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082526
Enrollment
Unknown
Registered
2024-03-31
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Insomnia Disorder

Interventions

Right precise target group:Personalized transcranial magnetic precise stimulation therapy
Left precise target group:Personalized transcranial magnetic precise stimulation therapy
Left traditional localization therapy group:Transcranial magnetic stimulation with traditional localization
normal control group:none
Right traditional localization therapy group:Transcranial magnetic stimulation with traditional localization

Sponsors

The People's Hospital of Guangxi Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1 age 18–70 years; 2 meet criteria for the diagnosis of chronic insomnia disorder; 3 Right-handed; 4 Medications that are able to stop treatment for insomnia during treatment. 5 Excluding any other systemic diseases that can cause brain dysfunction.

Exclusion criteria

Exclusion criteria: 1 patients with other sleep disorders such as moderate-severe sleep apnea syndrome ( OSAHS ) and restless legs syndrome; 2 with central nervous system diseases such as cerebrovascular disease, Parkinson’s disease, encephalitis, epilepsy, brain tumors, brain trauma, etc; 3 presence of alcohol abuse, history of drug abuse, or insomnia due to psychoactive substances; 4 unable to stop taking medications that affect sleep and the mind during treatment; 5 inability to cooperate with the examiner such as severe cardiopulmonary and cerebral disease; 6 presence of psychiatric disorders such as schizophrenia, etc; 7 patients with moderate and higher levels of anxiety and depression; 8 those who fail to cooperate with completion of the corresponding assessment and examination and withdraw midway; 9 There are contraindications to magnetic resonance examination (e.g., inability to remove a cardiac pacemaker, cochlear implant or other metallic implant, claustrophobia, etc.).

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Scale,PSQI;Structural Magnetic Resonance Imaging;fMRI;

Secondary

MeasureTime frame
Multib-valued multidirectional diffusion imaging sequences;ASL;Symptom Checklist 90,SCL-90;Athens Insomnia Scale, AIS;Self-rating anxiety scale,SAS;Self-rating Depression Scale,SDS;ESS;Sleep Symptom Checklist;Sleep hygiene awareness and habits scale.;ISI;

Countries

China

Contacts

Public ContactDemao Deng

The People's Hospital of Guangxi Autonomous Region

demaodeng@163.com+86 135 0788 0885

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026